Navigate to Other Sector


Healthcare Newsletter – August 2017

Sustaining Big Pharma Momentum in Biosimilars, Technology-driven Ventures Remain in the Race
Populist Price Control Approach Prevails in Healthcare Access for Medical Devices
Robust M&A Landscape Prevails in Pharma Contract Services
Gilead Jumps on Oncology Bandwagon Post Anti-infectives Success
Celebration Month for USFDA Medical Device Approvals
Funding Issues Prevail in the Under-appraised Anti-Infectives Market

Contact us to know more…

Discussion — No responses

Show Buttons
Hide Buttons